Form 4: Cytokinetics Director James Daly Reports Equity Grant

Director James M. Daly acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics, Inc.

Summary

• Director James M. Daly received an equity grant on May 27, 2026.
• The transaction included the acquisition of 2,851 shares of common stock at no cost.
• The director also received 4,301 non-qualified stock options with an exercise price of $77.15.
• The options vest on June 27, 2026, and expire on May 26, 2036.
• Following these transactions, the director holds 3,239 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it reflects standard administrative compensation practices rather than a strategic shift or operational update.

Positives

• Director alignment with shareholder interests through increased equity ownership.
• Standard compensation-related equity grant for a board member.

Negatives

• None identified.

Risks

• Market volatility affecting the value of the granted stock and options.
• The options are currently out-of-the-money relative to the exercise price if the market price is below $77.15.

Future Outlook

The filing does not provide forward-looking business guidance, as it is a standard disclosure of director compensation.

Industry Context

StockSavvy.ai notes that this filing represents routine director compensation within the biotechnology sector, where equity-based incentives are standard practice to align board members with long-term corporate performance.

Comparison to Industry Standards

• The grant of restricted stock and options is consistent with standard corporate governance practices for mid-to-large cap biotech firms.
• The vesting schedule and exercise price structure are typical for director compensation packages in the pharmaceutical industry.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation grant.

Next Steps

• Vesting of stock options on June 27, 2026.

Key Dates

Keywords

Cytokinetics, CYTK, Form 4, Insider Trading, Director Compensation, Equity Grant